Both are metabolized through proteolytic degradation rather than CYP450 liver enzymes, so there's no enzymatic competition
Because semaglutide targets receptors at the interface between the gut and the brain, gastrointestinal symptoms are part of its mechanism, not merely side effects
This means that people with diabetes taking semaglutide were more than four times more likely to receive a NAION diagnosis
Semaglutide and Tirzepatide are GLP-1 receptor agonists available in NYC that aid in weight loss by enhancing feelings of fullness, reducing appetite, and improving metabolic function
In diabetic neuropathy, microangiopathy damages these vessels, starving nerves of the resources needed for survival and repair
Mood: Find your balance, find your clarity